These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 39296452)

  • 1. Immunohistochemistry of p53 surrogates
    Kurihara Y; Honda T; Takemoto A; Seto K; Endo S; Tanimoto K; Kirimura S; Kobayashi M; Baba S; Nakashima Y; Wakejima R; Sakakibara R; Ishibashi H; Inazawa J; Tanaka T; Miyazaki Y; Okubo K
    JTCVS Open; 2024 Aug; 20():183-193. PubMed ID: 39296452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non-small cell lung cancer.
    Honda T; Seto K; Endo S; Takemoto A; Tanimoto K; Kobayashi M; Kitano M; Sakakibara R; Mitsumura T; Ishibashi H; Inazawa J; Tanaka T; Miyazaki Y; Okubo K
    Cancer Med; 2023 Oct; 12(19):19406-19413. PubMed ID: 37712717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma.
    Chang JG; Chen CC; Wu YY; Che TF; Huang YS; Yeh KT; Shieh GS; Yang PC
    Oncotarget; 2016 Nov; 7(45):73664-73680. PubMed ID: 27655641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world Comparison of P53 Immunohistochemistry and TP53 Mutation Analysis Using Next-generation Sequencing.
    Lee H; Cho YA; Kim DG; Son JY; Cho EY
    Anticancer Res; 2024 Sep; 44(9):3983-3994. PubMed ID: 39197898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of genetic alterations on outcomes of patients with stage I nonsmall cell lung cancer: An analysis of the cancer genome atlas data.
    Xu S; Wang Y; Ren F; Li X; Ren D; Dong M; Chen G; Song Z; Chen J
    Cancer Med; 2020 Oct; 9(20):7686-7694. PubMed ID: 32857918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
    Lee JK; Lee J; Kim S; Kim S; Youk J; Park S; An Y; Keam B; Kim DW; Heo DS; Kim YT; Kim JS; Kim SH; Lee JS; Lee SH; Park K; Ku JL; Jeon YK; Chung DH; Park PJ; Kim J; Kim TM; Ju YS
    J Clin Oncol; 2017 Sep; 35(26):3065-3074. PubMed ID: 28498782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes.
    Wang P; Wang F; He H; Chen Y; Lin H; Chen P; Chen X; Liu S
    Ann Transl Med; 2021 Aug; 9(16):1330. PubMed ID: 34532467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
    J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma.
    Kortekaas KE; Solleveld-Westerink N; Tessier-Cloutier B; Rutten TA; Poelgeest MIE; Gilks CB; Hoang LN; Bosse T
    Histopathology; 2020 Jul; 77(1):92-99. PubMed ID: 32236967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
    Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
    Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort.
    Machado-Rugolo J; Baldavira CM; Prieto TG; Olivieri EHR; Fabro AT; Rainho CA; Castelli EC; Ribolla PEM; Ab'Saber AM; Takagaki T; Nagai MA; Capelozzi VL
    Braz J Med Biol Res; 2023; 56():e12488. PubMed ID: 37042869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
    La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
    Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
    Karamurzin Y; Leitao MM; Soslow RA
    Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
    Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
    J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma.
    Liu DH; Zhao ZR; Lin YB; Zhou WJ; Hou JY; Ye ZH; Long H
    Ann Surg Oncol; 2019 Jun; 26(6):1934-1941. PubMed ID: 30820786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer.
    Hwang HJ; Nam SK; Park H; Park Y; Koh J; Na HY; Kwak Y; Kim WH; Lee HS
    J Pathol Transl Med; 2020 Sep; 54(5):378-386. PubMed ID: 32601264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.
    Ma X; Le Teuff G; Lacas B; Tsao MS; Graziano S; Pignon JP; Douillard JY; Le Chevalier T; Seymour L; Filipits M; Pirker R; Jänne PA; Shepherd FA; Brambilla E; Soria JC; Hainaut P;
    J Thorac Oncol; 2016 Jun; 11(6):850-61. PubMed ID: 26899019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the prognostic significance of p53 and TP53 mutations in HPV-negative hypopharyngeal carcinoma patients: a 5-year follow-up retrospective study.
    Huang Q; Li F; Ji M; Lin L; Hu C
    BMC Cancer; 2023 Apr; 23(1):324. PubMed ID: 37024846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.